Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aficamten - Cytokinetics

Next Previous
Drug Profile

Aficamten - Cytokinetics

Alternative Names: BAY-3723113; CK 3773274; CK-274

Latest Information Update: 22 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytokinetics
  • Developer Corxel Pharmaceuticals; Cytokinetics
  • Class Amides; Cardiovascular therapies; Heart failure therapies; Indenes; Oxadiazoles; Pyrazoles; Small molecules
  • Mechanism of Action Cardiac myosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypertrophic cardiomyopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hypertrophic cardiomyopathy

Most Recent Events

  • 20 Jun 2025 Bayer plans a phase III CAMELLIA-HCM trial for Hypertrophic cardiomyopathy in Japan (PO) (NCT07023341)
  • 13 May 2025 Adverse events and efficacy data from phase III MAPLE-HCM trial in Hypertrophic cardiomyopathy released by Cytokinetics
  • 01 May 2025 FDA assigns PDUFA action date of (26/12/2025) for Aficamten for hypertrophic cardiomyopathy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top